Thomas A Waldmann

List of Publications by Citations

433 papers	40,620 citations	107 h-index	188 g-index
458 ext. papers	43,751 ext. citations	11.8 avg, IF	7.28 L-index

#	Paper	IF	Citations
433	Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. *Cell*, **1981**, 27, 583-91	56.2	844
432	Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. *Nature*, **1984**, 311, 626-31	50.4	831
431	The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. *Nature Reviews Immunology*, **2006**, 6, 595-601	36.5	800
430	A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. *Nature*, **1982**, 300, 267-9	50.4	795
429	IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. *Immunity*, **2002**, 17, 537-47	32.3	703
428	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9571-6	11.5	692
427	Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. *New England Journal of Medicine*, **1985**, 313, 79-84	59.2	681
426	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature*, **2012**, 490, 116-20	50.4	600
425	The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. *Annual Review of Immunology*, **1999**, 17, 19-49	34.7	592
424	A humanized antibody that binds to the interleukin 2 receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 10029-33	11.5	531
423	Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. *New England Journal of Medicine*, **1983**, 309, 1593-9	59.2	514
422	Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. *Proceedings of the National Academy of Sciences of the United States of America*, **1984**, 81, 5214-8	11.5	514
421	Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5941-6	11.5	481
420	Immunotherapy: past, present and future. *Nature Medicine*, **2003**, 9, 269-77	50.5	455
419	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 1969-74	11.5	441
418	Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. *Journal of Clinical Investigation*, **1983**, 71, 301-13	15.9	433
417	Expression of interleukin 2 receptors on activated human B cells. *Journal of Experimental Medicine*, **1984**, 160, 1450-66	16.6	429

416	Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8053-8	11.5	421
415	The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. *Science*, **1986**, 232, 727-32	33.3	420
414	Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1981**, 78, 7096-100	11.5	401
413	IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. *Immunity*, **1996**, 4, 329-36	32.3	397
412	A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. *Nature*, **1989**, 339, 394-7	50.4	397
411	Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. *Journal of Clinical Oncology*, **2015**, 33, 74-82	2.2	394
410	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer Cell*, **2012**, 21, 723-37	24.3	386
409	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. *Journal of Clinical Oncology*, **2000**, 18, 1622-36	2.2	379
408	Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 9694-8	11.5	377
407	Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. *New England Journal of Medicine*, **1975**, 293, 887-92	59.2	375
406	The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 4940-4	11.5	362
405	IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 11445-50	11.5	341
404	Clustered arrangement of immunoglobulin lambda constant region genes in man. *Nature*, **1981**, 294, 536-40	50.4	338
403	A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 4935-9	11.5	337
402	Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. *Nature*, **1984**, 312, 641-3	50.4	314
401	Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells. *Nature*, **1981**, 290, 368-72	50.4	314
400	Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. *Nature*, **2011**, 471, 220-4	50.4	306
399	Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. *Nature*, **1998**, 391, 700-3	50.4	303

398	Monoclonal antibodies in diagnosis and therapy. *Science*, **1991**, 252, 1657-62	33.3	298
397	Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 8705-8	11.5	295
396	Rearrangements of genes for the antigen receptor on T cells as markers of lineage and clonality in human lymphoid neoplasms. *New England Journal of Medicine*, **1985**, 313, 776-83	59.2	295
395	The multi-subunit interleukin-2 receptor. *Annual Review of Biochemistry*, **1989**, 58, 875-911	29.1	294
394	The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 10128-32	11.5	294
393	Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 4522-6	11.5	276
392	Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 7462-6	11.5	265
391	The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. *Journal of Experimental Medicine*, **1967**, 126, 207-21	16.6	249
390	Interleukin-15 biology and its therapeutic implications in cancer. *Trends in Pharmacological Sciences*, **2012**, 33, 35-41	13.2	246
389	Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 13897-902	11.5	243
388	Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. *Proceedings of the National Academy of Sciences of the United States of America*, **1985**, 82, 4230-4	11.5	236
387	Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 2031-5	11.5	228
386	Human immunoglobulin D segments encoded in tandem multigenic families. *Nature*, **1981**, 294, 631-5	50.4	218
385	Superior T memory stem cell persistence supports long-lived T cell memory. *Journal of Clinical Investigation*, **2013**, 123, 594-9	15.9	216
384	The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. *Journal of Clinical Investigation*, **1972**, 51, 2916-27	15.9	215
383	Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. *Cancer*, **1977**, 40, 2136-51	6.4	208
382	A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. *Nature Medicine*, **2011**, 17, 604-9	50.5	207
381	Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. *Blood*, **2005**, 105, 721-7	2.2	202

380	Characterization of the human receptor for T-cell growth factor. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 6957-61	11.5	201
379	Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. *Annals of Internal Medicine*, **1978**, 88, 226-38	8	201
378	Human gamma-chain genes are rearranged in leukaemic T cells and map to the short arm of chromosome 7. *Nature*, **1985**, 316, 549-52	50.4	195
377	Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 2897-902	11.5	191
376	T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck. *Proceedings of the National Academy of Sciences of the United States of America* , **1991**, 88, 1996-2000	11.5	183
375	The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 5394-8	11.5	183
374	Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative S□ary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. *Journal of Clinical Investigation*, **1984**, 73, 1711-8	15.9	177
373	The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. *Cancer*, **1974**, 34, suppl:1510-5	6.4	175
372	Interleukin-2, interleukin-15, and their receptors. *International Reviews of Immunology*, **1998**, 16, 205-26	4.6	174
371	Cytokines in Cancer Immunotherapy. *Cold Spring Harbor Perspectives in Biology*, **2018**, 10,	10.2	173
370	Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. *New England Journal of Medicine*, **1983**, 309, 826-31	59.2	168
369	Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. *Journal of Immunology*, **2005**, 175, 112-23	5.3	164
368	Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 14444-9	11.5	163
367	The IL-2/IL-2 receptor system: a target for rational immune intervention. *Trends in Immunology*, **1993**, 14, 264-70		162
366	X-linked hypogammaglobulinemia and isolated growth hormone deficiency. *New England Journal of Medicine*, **1980**, 302, 1429-34	59.2	161
365	Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 3392-7	11.5	160
364	Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. *Journal of Immunology*, **2008**, 180, 2099-106	5.3	157
363	Immunodeficiency Disease and Malignancy. *Annals of Internal Medicine*, **1972**, 77, 605	8	156

362	Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 474-8	11.5	154
361	Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. *Journal of Immunological Methods*, **1980**, 33, 1-9	2.5	153
360	Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 2452-7	11.5	150
359	Only high-affinity receptors for interleukin 2 mediate internalization of ligand. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 1463-6	11.5	147
358	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. *Blood*, **1999**, 94, 3340-3348	2.2	145
357	Cytokines in the Treatment of Cancer. *Journal of Interferon and Cytokine Research*, **2019**, 39, 6-21	3.5	144
356	Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. *Clinical Cancer Research*, **2010**, 16, 6019-28	12.9	144
355	A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. *Clinical Cancer Research*, **2007**, 13, 958-64	12.9	143
354	Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. *Archives of Neurology*, **2009**, 66, 483-9		142
353	The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. *Annals of Internal Medicine*, **1986**, 105, 560-72	8	141
352	Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 6013-8	11.5	140
351	The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. *Journal of Urology*, **1977**, 118, 994-9	2.5	140
350	Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. *Lancet, The*, **1990**, 335, 497-500	40	138
349	Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. *Advances in Immunology*, **1982**, 32, 1-63	5.6	138
348	The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 588-93	11.5	137
347	Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. *New England Journal of Medicine*, **1978**, 298, 66-72	59.2	132
346	Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. *Journal of the National Cancer Institute*, **2004**, 96, 703-8	9.7	131
345	The suppressor-cell network in cancer (first of two parts). *New England Journal of Medicine*, **1978**, 299, 1281-4	59.2	131

344	A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. *Transplantation*, **1991**, 51, 107-13	1.8	130
343	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. *Blood*, **2011**, 117, 4787-95	2.2	127
342	Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5084-9	11.5	127
341	Variable amplification of immunoglobulin lambda light-chain genes in human populations. *Nature*, **1983**, 304, 172-4	50.4	126
340	Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 13134-9	11.5	124
339	NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. *Annals of Internal Medicine*, **1984**, 100, 543-57	8	124
338	Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. *New England Journal of Medicine*, **2018**, 378, 1947-1948	59.2	122
337	The use of antibodies against the IL-2 receptor in transplantation. *Current Opinion in Immunology*, **1998**, 10, 507-12	7.8	119
336	Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. *Journal of Clinical Immunology*, **2007**, 27, 1-18	5.7	119
335	Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. *Blood*, **2006**, 108, 1021-9	2.2	118
334	Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. *New England Journal of Medicine*, **1976**, 295, 1237-40	59.2	118
333	IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 5201-6	11.5	117
332	The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. *Cancer Immunology Research*, **2015**, 3, 219-27	12.5	114
331	Evidence for a defect in "switch" T cells in patients with immunodeficiency and hyperimmunoglobulinemia M. *New England Journal of Medicine*, **1986**, 314, 409-13	59.2	114
330	IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 15154-9	11.5	113
329	Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. *Journal of Autoimmunity*, **2003**, 21, 283-93	15.5	110
328	Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 3845-50	11.5	110
327	Discordance of human chorionic gonadotropin and alpha-fetoprotein in testicular teratocarcinomas. *Cancer*, **1973**, 31, 1065-8	6.4	109

326	Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 7513-8	11.5	107
325	IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 11082-7	11.5	107
324	Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. *Journal of Experimental Medicine*, **2014**, 211, 2497-505	16.6	105
323	Normal human B cells display ordered light chain gene rearrangements and deletions. *Journal of Experimental Medicine*, **1982**, 156, 975-85	16.6	104
322	The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor. *American Journal of Medicine*, **1961**, 31, 318-24	2.4	101
321	Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. *Immunity*, **2015**, 42, 826-38	32.3	100
320	The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. *Microbes and Infection*, **2012**, 14, 247-61	9.3	98
319	Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. *Cancer Research*, **2002**, 62, 1083-6	10.1	98
318	Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography. *Magnetic Resonance in Medicine*, **2003**, 50, 758-66	4.4	97
317	The arrangement of immunoglobulin and T cell receptor genes in human lymphoproliferative disorders. *Advances in Immunology*, **1987**, 40, 247-321	5.6	97
316	Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 15849-54	11.5	96
315	Frequent STAT5B mutations in hepatosplenic T-cell lymphomas. *Leukemia*, **2014**, 28, 2244-8	10.7	95
314	Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. *Blood*, **2002**, 100, 208-16	2.2	95
313	Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 3137-41	11.5	95
312	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. *Clinical Cancer Research*, **2018**, 24, 1525-1535	12.9	95
311	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. *Journal of Clinical Oncology*, **2019**, 37, 677-687	2.2	94
310	Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 4215-8	11.5	92
309	Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 7246-50	11.5	92

308	Testicular germ-cell neoplasms: recent advances in diagnosis and therapy. *Annals of Internal Medicine*, **1979**, 90, 373-85	8	91
307	Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis. *Journal of Cellular Biochemistry*, **1991**, 46, 302-11	4.7	90
306	Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. *New England Journal of Medicine*, **1989**, 321, 370-4	59.2	90
305	The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. *Cancer*, **1976**, 37, 215-9	6.4	90
304	First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. *Blood Advances*, **2019**, 3, 1970-1980	7.8	90
303	Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 1891-5	11.5	89
302	Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. *Annual Review of Immunology*, **2017**, 35, 533-550	34.7	87
301	Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 7970-5	11.5	86
300	Suppressor cells in neoplastic disease. *Journal of the National Cancer Institute*, **1978**, 61, 5-11	9.7	86
299	Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. *Cancer Research*, **2003**, 63, 271-6	10.1	86
298	Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. *Blood*, **2010**, 116, 3238-48	2.2	85
297	A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh□t□ disease. *Ocular Immunology and Inflammation*, **2007**, 15, 63-70	2.8	85
296	Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 2878-82	11.5	84
295	The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15. *Journal of Biological Chemistry*, **2000**, 275, 30653-9	5.4	82
294	Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. *Journal of Clinical Investigation*, **1990**, 86, 2093-8	15.9	81
293	miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic □ cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 476-81	11.5	80
292	Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 18648-53	11.5	80
291	Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. *Journal of Immunology*, **2001**, 166, 2602-9	5.3	79

290	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. *Cancer Research*, **2003**, 63, 6453-7	10.1	79
289	A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation. *Retrovirology*, **2015**, 12,	3.6	78
288	ITK and IL-15 support two distinct subsets of CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 12075-80	11.5	78
287	Viral Activation of Interleukin-15 (IL-15): Characterization of a Virus-Inducible Element in the IL-15 Promoter Region. *Journal of Virology*, **2002**, 76, 6864-6864	6.6	78
286	Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. *Journal of the National Cancer Institute*, **1990**, 82, 1050-4	9.7	78
285	Ataxia-telangiectasis: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia. *Annals of Internal Medicine*, **1983**, 99, 367-79	8	78
284	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 6187-92	11.5	77
283	The suppressor-cell network in cancer (second of two parts). *New England Journal of Medicine*, **1978**, 299, 1335-41	59.2	77
282	High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. *Journal of Autoimmunity*, **2008**, 31, 91-7	15.5	76
281	Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 2592-7	11.5	76
280	The multichain interleukin-2 receptor: a target for immunotherapy. *Annals of Internal Medicine*, **1992**, 116, 148-60	8	76
279	The IL-2/IL-15 receptor systems: targets for immunotherapy. *Journal of Clinical Immunology*, **2002**, 22, 51-6	5.7	75
278	FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. *Blood*, **2011**, 118, 3911-21	2.2	72
277	Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. *Oncogene*, **2007**, 26, 3699-703	9.2	72
276	GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines. *FEBS Journal*, **2002**, 269, 1199-208		72
275	The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 8291-5	11.5	72
274	Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. *Journal of Clinical Investigation*, **1971**, 50, 2331-8	15.9	72
273	Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 16619-24	11.5	71

272	Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. *Clinical Cancer Research*, **2004**, 10, 7712-20	12.9	71
271	Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14308-13	11.5	71
270	Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. *Journal of Clinical Investigation*, **1984**, 74, 966-71	15.9	70
269	Survival adjustment of mature dendritic cells by IL-15. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 8662-7	11.5	69
268	Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 8759-63	11.5	69
267	Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. *Journal of Clinical Investigation*, **1983**, 71, 282-95	15.9	69
266	Effective cancer therapy through immunomodulation. *Annual Review of Medicine*, **2006**, 57, 65-81	17.4	68
265	Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. *Annals of Neurology*, **1998**, 44, 942-7	9.4	65
264	Contrasting Roles of IL-2 and IL-15 in the Life and Death of Lymphocytes. *Immunity*, **2001**, 14, 105-110	32.3	65
263	The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. *Journal of Investigative Dermatology Symposium Proceedings*, **2013**, 16, S28-30	1.1	64
262	NIH conference. Molecular genetic analysis of human lymphoid neoplasms. Immunoglobulin genes and the c-myc oncogene. *Annals of Internal Medicine*, **1985**, 102, 497-510	8	64
261	Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes. *Cellular Immunology*, **1987**, 109, 318-31	4.4	63
260	IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. *Blood*, **2011**, 118, 6845-8	2.2	62
259	The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. *Arthritis Research*, **2002**, 4 Suppl 3, S161-7		62
258	Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. *Journal of the National Cancer Institute*, **1989**, 81, 914-23	9.7	62
257	Impaired lymphocyte transformation in intestinal lymphangiectasia: evidence for at least two functionally distinct lymphocyte populations in man. *Journal of Clinical Investigation*, **1972**, 51, 1319-25	15.9	62
256	Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. *Journal of Virology*, **2000**, 74, 7338-48	6.6	61
255	Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 401-6	11.5	60

254	Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. *Blood*, **2003**, 102, 284-8	2.2	60
253	Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. *Journal of Experimental Medicine*, **1996**, 183, 1587-602	16.6	60
252	Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 7329-33	11.5	60
251	IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E10915-E10924	11.5	60
250	Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. *Blood*, **2009**, 113, 4016-26	2.2	59
249	The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. *Leukemia and Lymphoma*, **2001**, 40, 287-94	1.9	59
248	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 12480-5	11.5	58
247	CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. *Blood*, **2011**, 117, 1938-46	2.2	58
246	Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. *Cancer Research*, **2004**, 64, 1460-7	10.1	58
245	Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. *Transplantation*, **1989**, 47, 55-9	1.8	58
244	Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. *Cancer Research*, **2004**, 64, 5825-9	10.1	57
243	IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. *Cancer Research*, **2015**, 75, 5187-5193	10.1	56
242	Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells. *Journal of Cell Science*, **2008**, 121, 627-33	5.3	56
241	A novel solid phase technology for high-throughput gene synthesis. *BioTechniques*, **2008**, 45, 340-3	2.5	55
240	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF/MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. *Blood*, **2000**, 95, 3939-3944	2.2	54
239	Deletional rearrangement in the human T-cell receptor alpha-chain locus. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 8608-12	11.5	54
238	Anaphylactic reactions to IgA: a difficult transfusion problem. *American Journal of Clinical Pathology* , **1970**, 54, 618-21	1.9	54
237	IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 14559-64	11.5	52

236	Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. *Clinical Immunology*, **2014**, 155, 176-87	9	51
235	Interleukin-15 in the treatment of cancer. *Expert Review of Clinical Immunology*, **2014**, 10, 1689-701	5.1	51
234	Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. *Journal of Immunology*, **2009**, 182, 3063-71	5.3	51
233	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. *Blood*, **2019**, 134, 1406-1414	2.2	50
232	Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15R. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 13534-9	11.5	50
231	Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. *Arthritis Research*, **2004**, 6, 174-7		49
230	IL-15: the role of translational regulation in their expression. *Journal of Leukocyte Biology*, **1996**, 59, 476-80	6.9	49
229	Juxtaposition of the T-cell receptor alpha-chain locus (14q11) and a region (14q32) of potential importance in leukemogenesis by a 14;14 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 9287-91	11.5	49
228	IL-15 in the Combination Immunotherapy of Cancer. *Frontiers in Immunology*, **2020**, 11, 868	8.4	48
227	EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. *Clinical Cancer Research*, **2009**, 15, 2514-22	12.9	48
226	Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. *Cancer*, **1981**, 47, 328-32	6.4	48
225	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. *Clinical Cancer Research*, **2019**, 25, 4945-4954	12.9	47
224	IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56 NK Cells and Increases NK-Cell Cytokine Release Capabilities. *Cancer Immunology Research*, **2017**, 5, 929-938	12.5	47
223	Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. *Clinical Cancer Research*, **2008**, 14, 875-82	12.9	47
222	Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle. *Neoplasia*, **2005**, 7, 984-91	6.4	47
221	Polyclonal activation of human B lymphocytes by Nocardia water soluble mitogen (NWSM). *Immunological Reviews*, **1979**, 45, 69-92	11.3	47
220	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik. mAb in patients with T-cell large granular lymphocytic leukemia. *Blood*, **2013**, 121, 476-84	2.2	46
219	Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. *Blood*, **2004**, 104, 3355-7	2.2	46

218	Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. *Journal of Immunology*, **2002**, 169, 3120-30	5.3	46
217	B cell, helper T cell, and suppressor T cell abnormalities contribute to disordered immunoglobulin synthesis in patients following bone marrow transplantation. *Transplantation*, **1982**, 33, 184-90	1.8	46
216	Increased serum soluble IL-15R□levels in T-cell large granular lymphocyte leukemia. *Blood*, **2012**, 119, 137-43	2.2	45
215	Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. *Blood*, **2008**, 111, 5163-72	2.2	45
214	The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 2165-9	11.5	45
213	Immunoglobulin genes: rearrangement and translocation in human lymphoid malignancy. *Journal of Clinical Immunology*, **1984**, 4, 1-11	5.7	45
212	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. *Cancer Cell*, **2018**, 34, 286-297.e10	24.3	44
211	Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. *American Journal of Hematology*, **2017**, 92, 892-901	7.1	43
210	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E498-E505	11.5	43
209	Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. *Journal of Clinical Immunology*, **2013**, 33, 586-94	5.7	43
208	Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science. *Trends in Biotechnology*, **1986**, 4, 259-264	15.1	43
207	The erythropoiesis-stimulating factors produced by tumors. *Annals of the New York Academy of Sciences*, **1968**, 149, 509-15	6.5	43
206	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. *Clinical Cancer Research*, **2016**, 22, 310-8	12.9	42
205	Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3975-3980	11.5	42
204	IL-15 in the life and death of lymphocytes: immunotherapeutic implications. *Trends in Molecular Medicine*, **2003**, 9, 517-21	11.5	42
203	Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease. A molecular genetic evaluation of the immunoglobulin and T-cell antigen receptors. *Gastroenterology*, **1988**, 95, 364-70	13.3	41
202	Corticosteroid-responsive intestinal lymphangiectasia secondary to an inflammatory process. *New England Journal of Medicine*, **1979**, 300, 605-6	59.2	41
201	The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. *Cancer Research*, **2006**, 66, 8227-32	10.1	40

200	Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. *Cancer Research*, **2010**, 70, 1072-81	10.1	39
199	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E2039-46	11.5	38
198	Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. *Vaccine Journal*, **2010**, 17, 793-801		38
197	Augmented IL-15R expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. *Journal of Immunology*, **2012**, 188, 6156-64	5.3	38
196	A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions. *Immunology Letters*, **2008**, 116, 117-25	4.1	38
195	90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13045-50	11.5	37
194	Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. *Nuclear Medicine and Biology*, **1998**, 25, 89-93	2.1	37
193	Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. *Journal of the National Cancer Institute*, **2000**, 92, 1573-81	9.7	37
192	Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30). *Journal of Experimental Medicine*, **1980**, 151, 257-62	16.6	37
191	Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. *International Journal of Cancer*, **1997**, 70, 221-9	7.5	36
190	Development of antibodies and chimeric molecules for cancer immunotherapy. *Advances in Immunology*, **2006**, 90, 83-131	5.6	36
189	Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin. *Clinical Cancer Research*, **2004**, 10, 3137-46	12.9	36
188	Clustering of class I HLA oligomers with CD8 and TCR: three-dimensional models based on fluorescence resonance energy transfer and crystallographic data. *Journal of Immunology*, **2001**, 166, 5078-86	5.3	36
187	Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. *Annual Review of Immunology*, **1992**, 10, 675-704	34.7	36
186	In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells. *Journal of Experimental Medicine*, **1981**, 154, 1069-84	16.6	36
185	Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. *Journal of Virology*, **2007**, 81, 8774-83	6.6	35
184	IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 5676-81	11.5	34
183	Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. *Blood*, **2009**, 113, 1287-93	2.2	34

182	Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. *Leukemia Research*, **2006**, 30, 190-203	2.7	34
181	Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 14169-74	11.5	34
180	Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. *Nuclear Medicine and Biology*, **2001**, 28, 845-56	2.1	34
179	Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. *Gastroenterology*, **1981**, 80, 166-168	13.3	34
178	Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection. *New England Journal of Medicine*, **1987**, 317, 1516-20	59.2	33
177	Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells. *New England Journal of Medicine*, **1981**, 304, 1382-7	59.2	33
176	Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. *Journal of Experimental Medicine*, **2020**, 217,	16.6	33
175	Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. *Blood*, **2013**, 121, 2029-37	2.2	32
174	Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8444-8	11.5	32
173	Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. *Blood*, **2006**, 108, 1007-12	2.2	32
172	Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. *Blood*, **2010**, 116, 5948-56	2.2	31
171	Successful treatment with acyclovir of an immunodeficient patient infected simultaneously with multiple herpesviruses. *American Journal of Medicine*, **1981**, 70, 882-6	2.4	31
170	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 1624-9	11.5	30
169	Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. *Blood*, **2013**, 121, 5045-54	2.2	30
168	IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells. *European Journal of Immunology*, **2014**, 44, 3330-41	6.1	30
167	MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. *Journal of Immunological Methods*, **2009**, 348, 83-94	2.5	30
166	Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. *Blood*, **2006**, 108, 705-10	2.2	30
165	Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. *Bioconjugate Chemistry*, **2003**, 14, 1044-7	6.3	30

164	Infectious complications and immunodeficiency in patients with human T-cell lymphotropic virus I-associated adult T-cell leukemia/lymphoma. *Cancer*, **1995**, 75, 1598-607	6.4	30
163	The role of the radioimmunoassay of serum alpha-fetoprotein and human chorionic gonadotropin in the intensive chemotherapy and surgery of metastatic testicular tumors. *Journal of Urology*, **1978**, 119, 759-62	2.5	30
162	Antibody-based therapy of leukaemia. *Expert Reviews in Molecular Medicine*, **2009**, 11, e29	6.7	29
161	Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. *Blood*, **2005**, 105, 1231-6	2.2	29
160	Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 5146-51	11.5	29
159	Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 3344-7	11.5	27
158	Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15R□*Blood*, **2011**, 117, 4032-40	2.2	26
157	Vaccination with tumor cells expressing IL-15 and IL-15R□nhibits murine breast and prostate cancer. *Gene Therapy*, **2014**, 21, 393-401	4	25
156	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. *Clinical Cancer Research*, **2017**, 23, 35-42	12.9	24
155	Alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors. *Journal of Urology*, **1977**, 118, 593-6	2.5	24
154	Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,NQN",N"Qtetraacetic acid (DOTA)-biotin. *Cancer Research*, **2002**, 62, 5755-60	10.1	24
153	Micro-MRI methods to detect renal cysts in mice. *Kidney International*, **2004**, 65, 1511-6	9.9	23
152	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. *Hematology American Society of Hematology Education Program*, **2000**, 394-408	3.1	23
151	Human B lymphocytes express the p75 component of the interleukin 2 receptor. *Leukemia Research*, **1990**, 14, 263-71	2.7	23
150	IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective □chain cytokines, decreases leukemic T-cell viability. *Leukemia*, **2019**, 33, 1243-1255	10.7	23
149	IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter. *Journal of Immunology*, **2002**, 168, 5667-74	5.3	22
148	Isospora belli enteric infection in patients with human T-cell leukemia virus type I-associated adult T-cell leukemia. *American Journal of Medicine*, **1988**, 85, 435-8	2.4	22
147	Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer. *Digestive Diseases and Sciences*, **1980**, 25, 161-72	4	22

146	Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line. *Journal of Experimental Medicine*, **1981**, 154, 156-67	16.6	22
145	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. *Blood*, **2000**, 95, 3939-3944	2.2	22
144	Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model. *Leukemia*, **2015**, 29, 556-66	10.7	21
143	IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma. *American Journal of Pathology*, **2015**, 185, 3102-14	5.8	21
142	Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 18091-6	11.5	21
141	A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. *Vaccine*, **2009**, 27, 2121-7	4.1	21
140	Activators of protein kinase C and 5-azacytidine induce IL-2 receptor expression on human T lymphocytes. *Journal of Cellular Biochemistry*, **1985**, 27, 267-76	4.7	21
139	Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. *Human Gene Therapy*, **2009**, 20, 1143-56	4.8	20
138	How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis?. *AIDS Research and Human Retroviruses*, **2000**, 16, 1717-22	1.6	20
137	Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 1752-7	11.5	20
136	Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. *Molecular Cancer*, **2016**, 15, 15	42.1	19
135	IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease. *Journal of Immunology*, **2008**, 181, 1109-19	5.3	19
134	Interleukin-2 receptor-directed therapies for cutaneous lymphomas. *Hematology/Oncology Clinics of North America*, **2003**, 17, 1449-58	3.1	19
133	Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines. *AIDS Research and Human Retroviruses*, **2000**, 16, 709-13	1.6	19
132	-endocytosis of intact IL-15R L-15 complex from presenting cells into NK cells favors signaling for proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 522-531	11.5	19
131	JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. *Molecular and Cellular Endocrinology*, **2017**, 451, 66-70	4.4	18
130	Protection by universal influenza vaccine is mediated by memory CD4 T cells. *Vaccine*, **2018**, 36, 4198-4206	4.1	18
129	IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells. *Journal of Immunology*, **2008**, 180, 7276-86	5.3	18

128	Oligomerization of IL-2Ralpha. *Cytokine*, **2002**, 17, 82-90	4	18
127	Receptor-directed therapy of T-cell leukemias and lymphomas. *Journal of Immunotoxicology*, **2008**, 5, 235-48	3.1	17
126	Demonstration of delta rec-pseudo J alpha rearrangement with deletion of the delta locus in a human stem-cell leukemia. *Journal of Experimental Medicine*, **1989**, 170, 339-42	16.6	17
125	Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15R in human monocytes and dendritic cells. *Journal of Biological Chemistry*, **2012**, 287, 40328-38	5.4	16
124	Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. *Virology*, **1997**, 237, 209-16	3.6	16
123	Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein. *Nuclear Medicine and Biology*, **2006**, 33, 469-80	2.1	16
122	Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. *Nuclear Medicine and Biology*, **2004**, 31, 357-64	2.1	16
121	Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. *Nuclear Medicine and Biology*, **2004**, 31, 1061-71	2.1	16
120	The interleukin-2 receptor on malignant cells: a target for diagnosis and therapy. *Cellular Immunology*, **1986**, 99, 53-60	4.4	16
119	ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. *Leukemia and Lymphoma*, **2003**, 44 Suppl 3, S107-13	1.9	15
118	Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha. *Biochemical and Biophysical Research Communications*, **2001**, 285, 1302-8	3.4	15
117	Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. *Cytokine*, **1999**, 11, 1065-75	4	15
116	The IL-2/IL-2 receptor system: a target for rational immune intervention. *Trends in Pharmacological Sciences*, **1993**, 14, 159-64	13.2	15
115	Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. *Transplantation*, **1989**, 48, 415-20	1.8	15
114	IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2R therapies. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 21120-21130	11.5	14
113	Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. *OncoImmunology*, **2014**, 3, e959321	7.2	14
112	Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys. *Vaccine*, **2010**, 28, 7081-91	4.1	14
111	Colorectal carcinoma rearranges cell surface protein topology and density in CD4+ T cells. *Biochemical and Biophysical Research Communications*, **2007**, 361, 202-7	3.4	14

110	Synthesis and biodistribution study of a new 211At-calix[4]arene complex. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2000**, 43, 1219-1225	1.9	14
109	Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation. *Transplantation*, **1990**, 50, 760-5	1.8	14
108	Immunoglobulin and T cell antigen receptor gene arrangements indicate that the immune response in autoimmune thyroid disease is polyclonal. *Journal of Clinical Endocrinology and Metabolism*, **1988**, 66, 958-63	5.6	14
107	MHC I Expression Regulates Co-clustering and Mobility of Interleukin-2 and -15 Receptors in T Cells. *Biophysical Journal*, **2016**, 111, 100-12	2.9	13
106	Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. *Blood*, **2012**, 120, 1816-9	2.2	13
105	Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. *Nuclear Medicine and Biology*, **2002**, 29, 139-46	2.1	13
104	Identification of a Receptor Antagonist That Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21. *Gastroenterology*, **2020**, 158, 625-637.e13	13.3	13
103	The meandering 45-year odyssey of a clinical immunologist. *Annual Review of Immunology*, **2003**, 21, 1-27	34.7	12
102	Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 1025-8	2.9	12
101	Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization. *Biotechnology Progress*, **2012**, 28, 497-507	2.8	11
100	Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates. *Bioconjugate Chemistry*, **2002**, 13, 786-91	6.3	11
99	The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro. *Clinical Immunology and Immunopathology*, **1989**, 52, 447-59		11
98	A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models. *Clinical Cancer Research*, **2020**, 26, 4093-4106	12.9	11
97	Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurements. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2005**, 1744, 176-98	4.9	10
96	Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia. *Retrovirology*, **2014**, 11, 43	3.6	9
95	Distinct spatial relationship of the interleukin-9 receptor with interleukin-2 receptor and major histocompatibility complex glycoproteins in human T lymphoma cells. *ChemPhysChem*, **2014**, 15, 3969-78	3.2	9
94	Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience. *Leukemia and Lymphoma*, **2008**, 49, 439-46	1.9	9
93	Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor. *Transplantation*, **1992**, 54, 963-8	1.8	9

92	Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 6478-82	11.5	9
91	T cell disorders in primary immunodeficiency diseases. *Seminars in Immunopathology*, **1978**, 1, 239-264		9
90	Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML. *Blood*, **2012**, 120, 894-894	2.2	9
89	Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS). *Journal of Clinical Immunology*, **2015**, 35, 661-7	5.7	8
88	Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes. *PLoS ONE*, **2015**, 10, e0143001	3.7	8
87	Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells. *Aids*, **2008**, 22, 1739-48	3.5	8
86	Fc IgM receptors on human lymphoblastoid B cell lines. *European Journal of Immunology*, **1978**, 8, 274-8	6.1	8
85	Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1437-1448	4.9	7
84	A pre-translational defect in a case of human mu heavy chain disease. *Molecular Immunology*, **1986**, 23, 725-32	4.3	7
83	Neoplasms of immunoregulatory T cells in clinical investigation. *Journal of Investigative Dermatology*, **1980**, 74, 267-71	4.3	7
82	Results From a First-in-Human Study of BNZ-1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (□) Family of Cytokines. *Journal of Clinical Pharmacology*, **2020**, 60, 264-273	2.9	7
81	NF-B-induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	7
80	Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin Lymphoma. *Cancer Biotherapy and Radiopharmaceuticals*, **2020**, 35, 249-261	3.9	7
79	The interleukin-2 receptor on normal and malignant lymphocytes. *Advances in Experimental Medicine and Biology*, **1987**, 213, 129-37	3.6	7
78	Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. *Leukemia and Lymphoma*, **2018**, 59, 1466-1469	1.9	6
77	Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells. *Biophysical Journal*, **2018**, 114, 2473-2482	2.9	6
76	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. *Hematology American Society of Hematology Education Program*, **2000**, 2000, 394-408	3.1	6
75	The interleukin-2 receptor: a target for immunotherapy. *Annals of the New York Academy of Sciences*, **1993**, 685, 603-10	6.5	6

74	Lymphokine receptor-directed therapy: a model of immune intervention. *Journal of Clinical Immunology*, **1990**, 10, 19S-28S; discussion 28S-29S	5.7	6
73	Immunodeficiency: immunoregulation and immunogenetics. *Clinical Immunology and Immunopathology*, **1986**, 40, 25-36		6
72	Characteristics of Multiple Myeloma as an Immunodeficiency Disease **1980**, 151-169		6
71	Loss of cytotoxicity and gain of cytokine production in murine tumor-activated NK cells. *PLoS ONE*, **2014**, 9, e102793	3.7	6
70	Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies **2021**, 9,		6
69	Clinical trial of a humanized anti-IL-2/IL-15 receptor chain in HAM/TSP. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1383-1394	5.3	5
68	A new domain in the Toll/IL-1R domain-containing adaptor inducing interferon- factor protein amino terminus is important for tumor necrosis factor- receptor-associated factor 3 association, protein stabilization and interferon signaling. *Journal of Innate Immunity*, **2014**, 6, 377-93	6.9	5
67	Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection. *Human Vaccines and Immunotherapeutics*, **2013**, 9, 1841-8	4.4	5
66	Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric energy transfer study. *European Biophysics Journal*, **2005**, 34, 127-43	1.9	5
65	Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency. *Clinical Immunology and Immunopathology*, **1991**, 61, S37-46		5
64	Blockade of IL-15 Utilizing Bnz-1, a Selective Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial. *Blood*, **2019**, 134, 2835-2835	2.2	5
63	Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. *Leukemia and Lymphoma*, **2019**, 60, 2062-2066	1.9	5
62	Minimum degree of overlap between IL-9R and IL-2R on human T lymphoma cells: A quantitative CLSM and FRET analysis. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2018**, 93, 1106-1117	4.6	5
61	The interleukin-2 receptor: a target for immunotherapy. *Advances in Experimental Medicine and Biology*, **1992**, 323, 57-66	3.6	5
60	Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody. *Leukemia*, **1998**, 12, 982-91	10.7	4
59	The multichain interleukin-2-receptor: A target for immunotherapy of patients with adult T-cell leukemia, autoimmune disorders and individuals receiving allografts. *Journal of Autoimmunity*, **1988** , 1, 641-653	15.5	4
58	Metabolism of Immunoglobulins. *Clinical Immunobiology*, **1976**, 71-95		4
57	Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 28980-28991	11.5	4

56	Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance. *Frontiers in Immunology*, **2021**, 12, 657293	8.4	4
55	NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice. *Cellular Immunology*, **2020**, 352, 104081	4.4	3
54	GVL for ATL?. *Blood*, **2013**, 121, 6-7	2.2	3
53	A novel means of favorably tipping the balance between cytopathic and regulatory T cells. *Immunity*, **2003**, 19, 465-6	32.3	3
52	1988 Presidential address of the Clinical Immunology Society: clinical immunology is everywhere and nowhere--strength or weakness?. *Clinical Immunology and Immunopathology*, **1989**, 51, 2-12		3
51	Evidence for Distinct IL-2 Receptors in Induction versus Maintenance of LAK Function. *Annals of the New York Academy of Sciences*, **1988**, 532, 480-481	6.5	3
50	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. *Blood*, **2011**, 118, 2575-2575	2.2	3
49	T Cell Disorders in Primary Immunodeficiency Diseases **1979**, 5-30		3
48	Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20 **2015**,		3
47	Analysis of Human Natural Killer Cell Metabolism. *Journal of Visualized Experiments*, **2020**,	1.6	3
46	Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. *Frontiers in Immunology*, **2020**, 11, 1813	8.4	3
45	Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases. *Molecular Cancer*, **2021**, 20, 86	42.1	3
44	Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. *Translational Oncology*, **2021**, 14, 100913	4.9	3
43	Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. *Retrovirology*, **2015**, 12,	3.6	2
42	Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. *Cancer Biotherapy and Radiopharmaceuticals*, **2009**, 24, 303-9	3.9	2
41	Selective dependence of H2-M3-restricted CD8 responses on IL-15. *Journal of Immunology*, **2012**, 188, 2575-82	5.3	2
40	Transmembrane Signals Mediated by IL-2 and IL-15 Control the Life and Death of Lymphocytes **2005**, 97-121		2
39	Methods for the study of the metabolism of immunoglobulins. *Methods in Enzymology*, **1985**, 116, 201-10	1.7	2

38	Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma. *Blood*, **2020**, 136, 23-24	2.2	2
37	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors **2021**, 9,		2
36	A Monoclonal Antibody to the Human Receptor for T Cell Growth Factor **1984**, 43-66		2
35	Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. *EMBO Journal*, **2011**, 30, 627-627	13	1
34	Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen. *Japanese Journal of Cancer Research*, **1998**, 89, 436-44		1
33	The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. 1976. *Journal of Urology*, **2002**, 167, 934-7; discussion 938	2.5	1
32	Advances in diagnosis of hematologic malignancies. *Hospital Practice (1995)*, **1986**, 21, 69-77	2.2	1
31	The proportion of TA, TG, and TM cells in various immunodeficiency and autoimmune disorders. *Cellular Immunology*, **1983**, 80, 105-14	4.4	1
30	Triple combination of BET plus PI3K and NF-B inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma.. *Blood Advances*, **2022**,	7.8	1
29	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. *Hematology American Society of Hematology Education Program*, **2000**, 2000, 394-408	3.1	1
28	Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.. *Blood*, **2008**, 112, 2010-2010	2.2	1
27	Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells. *Blood*, **2016**, 128, 503-503	2.2	1
26	IL-15 -Presentation Is an Autonomous, Antigen-Independent Process. *Journal of Immunology*, **2021**, 207, 2489-2500	5.3	1
25	Interleukin-15 **2003**, 478-484		1
24	Role and Molecular Biology of the Interleukin2-Interleukin-2 Receptor System in Health and Disease **1986**, 553-562		1
23	Engagement of lymphoma T cell receptors causes accelerated growth and the secretion of an NK cell-inhibitory factor. *Cellular Immunology*, **2020**, 357, 104213	4.4	1
22	A novel model of alternative NF-B pathway activation in anaplastic large cell lymphoma. *Leukemia*, **2021**, 35, 1976-1989	10.7	1
21	Genetic Rearrangements of Human Immunoglobulin Genes **1984**, 75-95		1

20	Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. *PLoS ONE*, **2015**, 10, e0141141	3.7	0
19	EGR1 Addiction in Diffuse Large B-cell Lymphoma. *Molecular Cancer Research*, **2021**, 19, 1258-1269	6.6	0
18	Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice. *Journal of Immunology*, **2021**, 207, 1194-1199	5.3	0
17	Immune Regulation33-44		
16	The metabolism branch: an exemplar of patient-oriented research. *Cancer Investigation*, **1995**, 13, 662-3	2.1	
15	A T-cell line with an unusual phenotype. *Cancer*, **1989**, 64, 1859-66	6.4	
14	Organization of the Human Immune System. *Dermatologic Clinics*, **1990**, 8, 593-607	4.2	
13	Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies. *Blood*, **2019**, 134, 1558-1558	2.2	
12	Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma. *Blood*, **2019**, 134, 3781-3781	2.2	
11	Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia. *Blood*, **2019**, 134, 3052-3052	2.2	
10	The Multichain Interleukin-2-Receptor: A Target for Immunotherapy of Patients with Adult T-cell Leukemia, Autoimmune Disorders and Individuals Receiving Allografts **1989**, 145-157		
9	The Multichain Interleukin-2 Receptor: From the Gene to the Bedside **1989**, 675-683		
8	Disorders of IL-2 Receptor Expression in HTLV-IAssociated Adult T Cell Leukemia **1989**, 126-141		
7	Adult T-cell Leukemia: Prospects for Immunotherapy **1991**, 319-334		
6	A Gain-of-Function CCR4 Mutations in Adult T-Cell Leukemia/Lymphoma (ATLL) Enhance the Chemotactic Abilities and PI3K/AKT Activation. *Blood*, **2014**, 124, 3566-3566	2.2	
5	T-T INTERACTIONS IN THE GENERATION OF HUMAN SUPPRESSOR EFFECTOR CELLS IN VITRO **1979** , 69-84		
4	Disorders of Suppressor T Cells in Immunodeficiency and Malignancy **1980**, 381-402		
3	Molecular Analysis of the Human Interleukin-2 Receptor **1985**, 8-20		

2 Interleukin-2 Receptors **1985**, 285-300

1 Molecular Cloning and Expression of cDNAS Encoding the Human Interleukin-2 Receptor **1985**, 185-195